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The natural history of polycythemia vera (PV) is marked by arterial and venous thromboembolism and 
evolution into myelofibrosis and/or acute myeloid leukaemia/myelodysplastic syndrome. 
One of the major goals of treatment is to reduce the thrombotic events which account for 40% of causes of 
mortality. Several trials have investigated the outcomes of various therapeutic approaches and underscored 
the importance of therapeutic phlebotomy (TP). The first PVSG prospective trial1 randomized 431 patients to 
receive either TP alone or TP combined with chlorambucil or radioactive phosphate (32P) and patients were 
then followed for 20 years. The median survival was 13, 11 and 9 years for patients randomly assigned to 
treatment with TP alone, radioactive phosphate and chlorambucil plus TP as needed, respectively. The study 
also showed an increased incidence of thrombosis among the group treated with TP alone, especially during 
the first 3 years (23% compared to 16% in the 32P treatment arm). However, compared to patients given 
myelosuppressive therapy, patients who were treated with TP alone, had a lower incidence of hematological 
malignancies and solid tumors. The authors concluded that TP provides the best overall survival but at the 
cost of increased risk of thrombosis during the first 3 years. One interpretation of these unexpected finding 
was attributed to the occurrence of thrombocytosis, a relative frequent event  after initiating TP. Then, PVSG 
conducted a trial2 in which phlebotomized patients were given high-dose aspirin and dipyridamole with the 
aim to reduce thrombosis, but the trial failed due to an increased incidence of gastrointestinal hemorrhage. In 
2004, the antithrombotic role of aspirin was demonstrated by the European collaboration on low-dose aspirin 
in polycythemia vera (ECLAP) placebo-controlled randomized clinical trial3 showing that low-dose aspirin 
can safely prevent thrombotic complications in patients with PV who have no contraindications to such 
treatment. Currently, hydroxyurea (HU) is recommended4,5 in patients who are at high risk of thrombosis, 
progressive disease or in those who cannot tolerate frequent therapeutic phlebotomies. Other therapeutic 
options include treatment with interferon-alpha,6 or ruxolitinib as shown in 2 recent randomized clinical 
trials.7,8  
Furthermore, there is now evidence from the Cytoreductive Therapy in Polycythemia Vera (CYTO-PV) 
randomized clinical trial,9 that therapeutic TP, aimed at keeping hematocrit (HCT) threshold <45%, 
represents the cornerstone in the therapeutic armamentarium of PV either alone in low-risk PV or as 
supplement of cytoreductive therapy in high risk patients. However, a recent retrospective study in a large 
cohort of PV patients,10 raised the issue that in patients receiving HU, frequent TP (>3 per year) enhanced the 
risk of major thrombosis. This finding may be relevant for clinical practice and, if confirmed, may support 
the use of second line therapy with JAK2-inhibitors drugs or interferon-alpha to reduce the thrombotic risk 
associated with higher frequency of TP. Therefore, we reviewed the  ECLAP and CYTO-PV database in 
which information on the frequency of phlebotomies and vascular events was available. 
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In the ECLAP database, a subgroup of 793 patients (48%) out of 1638 included in the ECLAP study, was 
treated with hydroxyurea for a median follow-up of 28 months. In these patients, clinical outcomes, 
treatments, and laboratory values during the follow-up were recorded at follow-up visits at 12, 24, 36, 48, 
and 60 months. For the purpose of this study, we calculated the total number of TP/time of follow-up and 
the number of TP per year, in HU treated patients and looked at the correlation between frequency of TP 
and thrombosis. Three groups were created: NO TP (n=313, 39%), 1-2 TP per year (n=340, 43%), 3 or 
more TP per year (n=140, 18%). Time to first thrombotic event from HU start was calculated in each 
group, censoring patients with no event at last visit or at time of HU discontinuation, whichever occurred 
first. A total of 79 major thrombosis were observed during the follow-up of these patients while receiving 
HU. As reported in Figure 1, the cumulative incidence of thrombosis was superimposable in the 3 groups 
prospectively evaluated. In the patients submitted up to 2 TP per year versus 3 or more TP per year, HCT 
median values were 44.73% (IQR: 41.05% - 47.00%) and 46.03% (IQR: 44.35% - 48.63%), respectively 
(p=0.102), but this small difference did not impact on the rate of incident thrombosis. Of note, in those 
patients requiring 3 or more TP per year, only 6 received more than 5 TP on annual basis and, in these 
latter cases, the incidence of thrombosis was not different in comparison with those treated with less than 
4 TP per year (Log-rank test, p=0.802). 
In the Italian randomized CYTO-PV trial, we assessed the benefit/risk profile of cytoreductive therapy 
with TP or HU aimed at maintaining HCT < 45% versus maintaining HCT in the range 45%–50% in 365 
patients meeting the 2008-WHO criteria of PV. For all patients, exposure to (and dose of) hydroxyurea, as 
well as exposure to (and number of) phlebotomies, were available every 6 months from randomization 
until the end of follow-up. The arm maintained at HCT target less than 45%, had a significant 4 times 
lower rate of cardiovascular death and major thrombosis than did the arm with a hematocrit target of 45 to 
50%. According to the therapy administered during the follow-up period, 3 categories were created: 
stable patients not requiring TP nor HU (n=36), patients on TP alone (n=92), and patients on HU alone or 
in combination with TP (n=237). As shown in Figure 2, the frequency of TP during follow-up in the 365 
patients (cohort A) was significantly higher in the low-HCT arm (p<0.000) than in high-HCT arm. The 
same trend was documented when analysis was restricted to patients under HU treatment alone or in 
combination with TP (cohort B) (p<0.000). In contrast, the dose of HU was not statistically different in 
the two arms of the study. Thus, more TP were needed to keep the threshold HCT<45% and in this way a 
3 fold lower thrombotic events were registered. 
The effect of frequent TP on the risk of thrombosis was estimated by a multivariable Cox proportional-
hazard model, adjusted for HCT arm and high-risk category (age of 65 years or older and/or previous 
thrombosis) and fitted in the cohort A and in cohort B (Table 1). Since the number of TP changed over 
time, a TP was treated as a time-dependent covariate (updated in the model every six months), to assess 
whether the increase in the number of phlebotomies during the follow-up was associated with the 
probability of having a thrombotic event. In the whole cohort (A), for every additional phlebotomy 
performed, no increased risk of thrombosis was seen (HR=0.92, 95% CI 0.67-1.26). Conversely, patients 
in the low-HCT arm (with higher median frequency of TP), had a 62% lower risk of thrombosis 
(HR=0.38, 95% CI 0.17-0.87) if compared with those in high-HCT arm. The same results were obtained 
in the cohort B, in which the HR of low-HCT arm was 0.37 (95% CI 0.13 - 1.04), not reaching the full 
statistical significance due to the smaller number of available events.  
In a separate  analysis of the two arms of the trial, the results were similar to those of the whole cohort. In 
particular, for every additional phlebotomy, the risk of thrombosis did not change neither in low-HCT 
arm (HR=1.18, 95% CI 0.81-1.73) nor in high-HCT arm (HR=0.71, 95% CI 0.42-1.22). This was also 
seen in the subgroup of patients receiving HU (in low-HCT arm: HR=0.72, 95% CI 0.26-1.96 and in 
high-HCT arm: HR=0.99, 95% CI 0.61-1.64), confirming the lack of association between the requirement 
of additional phlebotomies and the risk of thrombotic events. 
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All These results, based on a more powerful analysis in PV patients treated with HU in the settings of 
controlled prospective trials, do not confirm those recently reported by Alvarez-Larran et al,10 who 
showed in an observational cohort a correlation between the number of TP and a higher incidence of 
thrombosis in HU treated patients.  It should be underscored that the median value of HCT in the group 
treated with 3 or more phlebotomies (46.03%) of ECLAP study was lower than the median value of 
hematocrit in high-HCT arm of Cyto-PV trial (always above 47.5%) and that this latter value was 
comparable to the group treated with 3 or more phlebotomies of the Spanish cohort in which higher risk 
of thrombosis was reported. Clearly, the increased number of phlebotomies is obviously related to the 
need of reaching the target hematocrit level. Thus, it could be argued that the higher risk of thrombosis, 
might be related to an uncontrolled hematocrit value, rather than to the use of phlebotomies per se.  
In conclusion, our results indicate that the frequency of phlebotomies in PV patients on HU does not 
represent a risk factor for future thrombosis in PV patients and do not support the need to shift from HU 
plus TP to second line drugs, and indirectly reinforce that a low HCT is the key variable to reduce the 
thrombotic risk in PV patients.  
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Tables 
 
Table 1. Hazard Ratio (HR) of time to thrombotic events, and 95% confidence intervals (CI), estimated by a 
multivariable Cox proportional-hazard model fitted in the whole cohort (column A) and among patients 
treated with hydroxyurea alone or in combination to phlebotomies (column B) 
  
All cohort (A) 
N = 365 p 
HU +/- TP (B) 
N = 237 p 
  HR (95% CI) HR (95% CI) 
N° of TP*  0.92 (0.67 - 1.26) 0.611 0.88 (0.57 - 1.38) 0.587 
Low-HCT arm 0.38 (0.17 - 0.87) 0.023 0.37 (0.13 - 1.04) 0.060 
High risk category** 1.79 (0.71 - 4.47) 0.215 1.96 (0.45 - 8.58) 0.370 
HR: Hazard Ratio; 95% CI:95% Confidence Interval 
*The number of phlebotomies (TP) during follow-up was included in the model as a time-dependent variable 
**Patients were in the high-risk category if they were aged more than 65 years and/or if they had previous thrombosis 
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Legend to Figures 
Figure 1. Cumulative incidence of major thrombosis in PV patients under hydroxyurea (HU) 
treatment by number of therapeutic phlebotomies (TP) per year. In parenthesis are quoted number of 
events for each period. Test for trend of the failure function across three ordered groups are performed and 
the relative p-value reported. 
 
 
 
 
 
Figure 2. Mean number of therapeutic phlebotomies (TP) and doses of hydroxyurea (HU) during 
follow-up in the low/high-hematocrit (HCT) arm. (A) Whole cohort; (B) Patients treated with 
hydroxyurea alone or in combination with phlebotomies. The difference between the high/low-HCT arms in 
the number of  TP or HU dose over time was assessed using a repeated-measures mixed model (pTP: p-value 
for difference in the number of TP; pHU: p-value for difference in HU dose). 
 


